Semaglutide Long-Term Safety: What 5-Year Data Reveals

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Long-term data, particularly from the SELECT trial, confirms semaglutide's significant cardiovascular benefits in patients with overweight or obesity and established cardiovascular disease. While generally safe, continued monitoring for potential risks like thyroid C-cell tumors, pancreatitis, and gallbladder issues remains crucial, especially with prolonged use.

Semaglutide Long-Term Safety: Insights from Half a Decade of Data

For any medication intended for chronic use, long-term safety data is paramount. Semaglutide, a GLP-1 receptor agonist, has been a game-changer in managing type 2 diabetes and obesity, but patients and clinicians rightly question its safety profile over extended periods. Fortunately, accumulating evidence, including studies with follow-up periods extending to five years, provides a clearer picture of semaglutide’s long-term effects, particularly concerning cardiovascular health and potential adverse events.

The therapeutic benefits of semaglutide—improved glycemic control, significant weight loss, and appetite suppression—are well-established. These effects are mediated by its action as a GLP-1 mimetic, which slows gastric emptying, increases insulin secretion, and reduces glucagon. However, like all potent medications, understanding the full spectrum of its long-term impact is crucial for informed clinical decision-making. Unlike short-term interventions, chronic therapies require a deeper dive into safety.

Cardiovascular Benefits: A Landmark Finding

One of the most significant revelations from long-term semaglutide research comes from the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity). This landmark study, which followed over 17,000 participants with overweight or obesity and established cardiovascular disease for a mean of 39.8 months (approximately 3.3 years), demonstrated a remarkable 20% reduction in major adverse cardiovascular events (MACE) compared to placebo [1] [2]. This included a reduction in cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This finding extends previous observations from trials in patients with type 2 diabetes (like SUSTAIN-6) and firmly establishes semaglutide as a cardioprotective agent in a broader population.

The SELECT trial’s results underscore that semaglutide’s benefits extend beyond just weight loss; it actively improves cardiovascular health outcomes in high-risk individuals. This is a critical distinction, as many weight loss interventions do not demonstrate such direct cardiovascular protection. You’ll find that this data has significantly influenced clinical guidelines for obesity management.

Thyroid C-Cell Tumors: A Persistent Concern

A long-standing concern with GLP-1 receptor agonists, including semaglutide, has been the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This concern originated from rodent studies where semaglutide caused a dose-dependent increase in thyroid C-cell tumors [3]. However, human data has not consistently replicated this finding. Large observational studies and meta-analyses, some with follow-up periods exceeding 5 years, have generally not shown a statistically significant increase in the incidence of MTC in humans treated with semaglutide compared to other diabetes medications or placebo [4].

Despite this, the FDA label for semaglutide still carries a boxed warning regarding the risk of thyroid C-cell tumors, and it is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This cautious approach reflects the need for continued vigilance, especially given the long-term nature of treatment. Unlike other side effects, this is a rare but serious potential complication.

Pancreatitis and Gallbladder Issues: Ongoing Monitoring

Pancreatitis and gallbladder-related adverse events (such as cholelithiasis, or gallstones, and cholecystitis) are known risks associated with GLP-1 receptor agonists. Long-term data continues to show a small but increased risk of these conditions with semaglutide use. The mechanism is thought to be related to the medication’s effects on GI motility and potentially pancreatic enzyme secretion.

While the absolute risk remains low, it’s a factor that clinicians monitor closely. Patients experiencing severe abdominal pain, with or without nausea and vomiting, should seek immediate medical attention. You’ll find that the risk of gallstones can be higher with rapid weight loss from any method, so it’s not entirely unique to semaglutide, but the medication may contribute to it [5].

Other Long-Term Considerations

Beyond these specific concerns, long-term use of semaglutide has generally been well-tolerated, with common side effects like nausea, diarrhea, and constipation often subsiding over time as the body adapts. The benefits of sustained weight loss and improved metabolic parameters, including blood pressure and lipid profiles, contribute to an overall positive long-term risk-benefit ratio for many patients.

However, the long-term implications of semaglutide-induced delayed gastric emptying, particularly the rare but serious risk of gastroparesis, continue to be a subject of ongoing research and clinical attention. As discussed in previous articles, this is a distinct concern that requires careful monitoring.

Practical Takeaway

Five years of data, particularly from robust cardiovascular outcomes trials, strongly supports the long-term safety and significant cardiovascular benefits of semaglutide in appropriate patient populations. While the risk of thyroid C-cell tumors remains a theoretical concern from animal studies, human data has largely been reassuring, though the boxed warning and contraindications persist. Patients should be aware of the small but increased risks of pancreatitis and gallbladder issues. Always maintain open communication with your healthcare provider, reporting any new or worsening symptoms, to ensure that the benefits of semaglutide continue to outweigh any potential long-term risks for your individual health profile.

References

[1] Lincoff, A. M., et al. (2023). Semaglutide Effects on Cardiovascular Outcomes in Obesity. New England Journal of Medicine.